Tomeglovir
Alternative Names: BAY-38-4766Latest Information Update: 06 Oct 2006
Price :
$50 *
At a glance
- Originator Bayer
- Class Antivirals
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 06 Oct 2006 Discontinued - Phase-II for Cytomegalovirus infections treatment in Germany (PO)
- 06 Oct 2006 Discontinued - Phase-II for Cytomegalovirus infections treatment in USA (PO)
- 06 May 2003 Data presented at the 16th International Conference on Antiviral Research (ICAR-2003) have been added to the adverse events, pharmacokinetics and Viral Infections pharmacodynamics sections